For the 1.2 million patients with chronic heart failure in Japan, a wristwatch-type wearable device will be used to detect heart murmurs and changes in activity levels specific to heart failure and recommend that patients seek medical attention. After the consultation, doctors will adjust oral medication, ultimately reducing re-hospitalization due to worsening heart failure.
Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.
A startup using regenerative medicine technologies to produce and supply homogeneous, high-precision blood cells at scale. It streamlines infectious disease research and the evaluation of pharmaceuticals and functional materials for efficacy and safety, while also providing research cells, testing cells, and diagnostic kits.
Neocure prevents 30,000 children from going blind each year due to ROP using AI technology. ROP can be treated, but it is often hard to find in time. Our AI analyzes the risk for each baby, helping to prevent missed diagnoses in hospitals where there aren't enough eye specialists. By helping doctors focus on the most urgent cases, we can stop blindness caused by ROP.
We are a company that researches, develops, manufactures, and sells glycoconjugates, such as glycoproteins and glycopeptides. The development of ADCs using glycan linkers is progressing in the pharmaceutical industry, and we are capable of conducting basic research and contract-based research on these products as well as supplying large quantities of API raw materials. We are also conducting new research and development using glycans, including in mRNA vaccines and other macromolecular LNPs. Our in-house glycosylated somatostatin is currently undergoing clinical trials (Phase 2a), and we plan to out-license the technology in the future.
